Department of Human Genetics, National Institute of Health Doutor Ricardo Jorge, Porto, Portugal.
Adv Exp Med Biol. 2019;1157:133-177. doi: 10.1007/978-3-030-19966-1_7.
In recent years, the RNA molecule became one of the most promising targets for therapeutic intervention. Currently, a large number of RNA-based therapeutics are being investigated both at the basic research level and in late-stage clinical trials. Some of them are even already approved for treatment. RNA-based approaches can act at pre-mRNA level (by splicing modulation/correction using antisense oligonucleotides or U1snRNA vectors), at mRNA level (inhibiting gene expression by siRNAs and antisense oligonucleotides) or at DNA level (by editing mutated sequences through the use of CRISPR/Cas). Other RNA approaches include the delivery of in vitro transcribed (IVT) mRNA or the use of oligonucleotides aptamers. Here we review these approaches and their translation into clinics trying to give a brief overview also on the difficulties to its application as well as the research that is being done to overcome them.
近年来,RNA 分子成为治疗干预最有前途的靶点之一。目前,大量基于 RNA 的治疗方法正在基础研究和晚期临床试验中进行研究。其中一些甚至已经被批准用于治疗。基于 RNA 的方法可以在 pre-mRNA 水平(通过使用反义寡核苷酸或 U1snRNA 载体进行剪接调节/校正)、mRNA 水平(通过 siRNA 和反义寡核苷酸抑制基因表达)或 DNA 水平(通过使用 CRISPR/Cas 编辑突变序列)发挥作用。其他 RNA 方法包括体外转录 (IVT) mRNA 的递送或寡核苷酸适体的使用。在这里,我们回顾了这些方法及其向临床的转化,试图简要概述其应用的困难以及正在进行的克服这些困难的研究。